September 21, 2016
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on today’s House Committee on Oversight and Government Reform hearing, “Reviewing the Rising Price of EpiPens:”
“For EpiPens, price concessions negotiated by pharmacy benefit managers (PBMs) have significantly reduced costs to the system while overall average patient cost share—including both copays and coinsurance—has decreased from 26% of list price in 2009 to 11% in 2016.
“Furthermore, a recent Deutsche Bank report challenges the credibility of Mylan’s assertion that others in the drug supply chain are to blame for its decision to raise prices. Mylan raised EpiPen prices by 600 percent even though combined costs for the rest of the supply chain (wholesalers, PBMs, retailers) are only a small fraction of that amount.”
Potential market-based solutions to address high drug prices that policymakers could consider include:
- Accelerating FDA approvals of drugs that face no competition;
- Making copay coupons an illegal kickback for all insurance that receives any federal subsidy; and
- Incentivizing greater use of biosimilars.
See PCMA’s new infographic: “The Facts on EpiPen Costs.”